Unite Acquisition 1 Corp.-linked Adaptin Bio opens Phase 1 trial of APTN-101 in EGFRvIII+ glioblastoma patients
APTN•Phase 1 trial opens for APTN-101
- Unite Acquisition 1 Corp. disclosed that Adaptin Bio opened enrollment for a Phase 1 trial of APTN-101 in EGFRvIII-positive glioblastoma.
- No clinical results have been presented; initial safety and tolerability findings are expected later as the first-in-human study progresses.
- The trial aims to determine whether APTN-101 can be administered safely while showing early signs of anti-tumor activity.
- Duke University will run the study, supporting Adaptin’s strategy to advance a brain-delivered immunotherapy platform into the clinic.
